LMAT Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 20.32% compared to LeMaitre Vascular's net margin of --. LeMaitre Vascular's return on equity of 13.37% beat Perspective Therapeutics's return on equity of --.

LeMaitre Vascular has a consensus price target of $98.78, signalling upside risk potential of 8.1%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 414.33%. Given that Perspective Therapeutics has higher upside potential than LeMaitre Vascular, analysts believe Perspective Therapeutics is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.933, which suggesting that the stock is 6.665% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.7%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are larger than Perspective Therapeutics quarterly revenues of --. LeMaitre Vascular's net income of $11.1M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, LeMaitre Vascular's price-to-earnings ratio is 49.93x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 9.71x versus 16.96x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 8.28%. LeMaitre Vascular's return on equity of 13.37% beat Globus Medical's return on equity of 2.27%.

LeMaitre Vascular has a consensus price target of $98.78, signalling upside risk potential of 8.1%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Globus Medical has higher upside potential than LeMaitre Vascular, analysts believe Globus Medical is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.933, which suggesting that the stock is 6.665% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.7%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than Globus Medical quarterly revenues of $625.7M. LeMaitre Vascular's net income of $11.1M is lower than Globus Medical's net income of $51.8M. Notably, LeMaitre Vascular's price-to-earnings ratio is 49.93x while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 9.71x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 14.25%. LeMaitre Vascular's return on equity of 13.37% beat Insulet's return on equity of 49.55%.

LeMaitre Vascular has a consensus price target of $98.78, signalling upside risk potential of 8.1%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 8.47%. Given that Insulet has higher upside potential than LeMaitre Vascular, analysts believe Insulet is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.933, which suggesting that the stock is 6.665% less volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.7%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than Insulet quarterly revenues of $543.9M. LeMaitre Vascular's net income of $11.1M is lower than Insulet's net income of $77.5M. Notably, LeMaitre Vascular's price-to-earnings ratio is 49.93x while Insulet's PE ratio is 45.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 9.71x versus 10.14x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 25.43%. LeMaitre Vascular's return on equity of 13.37% beat ResMed's return on equity of 23.76%.

LeMaitre Vascular has a consensus price target of $98.78, signalling upside risk potential of 8.1%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 9.49%. Given that ResMed has higher upside potential than LeMaitre Vascular, analysts believe ResMed is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.933, which suggesting that the stock is 6.665% less volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.7%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than ResMed quarterly revenues of $1.2B. LeMaitre Vascular's net income of $11.1M is lower than ResMed's net income of $311.4M. Notably, LeMaitre Vascular's price-to-earnings ratio is 49.93x while ResMed's PE ratio is 30.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 9.71x versus 7.09x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.